Latest news with #JNJ.N
Reuters
23-07-2025
- Business
- Reuters
Boston Scientific lifts annual profit forecast, sees smaller tariff impact
July 23 (Reuters) - Boston Scientific (BSX.N), opens new tab raised its annual profit forecast on Wednesday, banking on strong demand for its heart devices, and trimmed its expectation for tariff-related costs to half of the previously projected amount. Shares of the company rose 4.8% in morning trading following the results. "Based on the current schedule of expected tariffs, we now anticipate a full-year headwind of about $100 million, down from a $200 million estimate," CFO John Monson said during a call with analysts. The company expects to offset the remaining tariff impact through strong sales performance, favorable product mix and spending control, Monson added. A rise in surgical procedures has boosted sales for medical device makers such as Boston Scientific, helping counter broader concerns about healthcare spending. Executives credited strong trial results and expanded product indications for fueling physician adoption of key cardiovascular devices such as Watchman and Farapulse, the firm's main growth drivers that saw steady quarterly demand. The company said the proposed rules by the Centers for Medicare & Medicaid Services regarding certain cardiac procedures would further benefit its technologies. Farapulse, which is approved in the U.S. for some patients with intermittent atrial fibrillation, competes with Johnson & Johnson's (JNJ.N), opens new tab Varipulse and Medtronic's (MDT.N), opens new tab PulseSelect in the pulsed field ablation (PFA) market. Rival Johnson & Johnson last week posted strong medtech sales, aided by its heart devices, Varipulse and Trupulse. JP Morgan analyst Robbie Marcus said the profit forecast raise was larger than many had expected, especially given Boston Scientific is now moving past the initial U.S. rollout of Farapulse. "That said, the outlook still appears conservative to us," Marcus added. Boston Scientific now expects 2025 adjusted profit of $2.95 to $2.99 per share, up from its prior view of $2.87 to $2.94. It posted adjusted profit of 75 cents per share for the second quarter, topping analysts' average estimate of 72 cents, according to LSEG.
Reuters
30-04-2025
- Health
- Reuters
US FDA approves J&J's immune disorder drug
April 30 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's (JNJ.N), opens new tab drug to treat some patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday. The drug, which will be sold under the brand name Imaavy, was approved for patients with generalized myasthenia gravis - an immunity-related disorder that weakens the skeletal muscles, especially those in the eyes, mouth, throat and limbs. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. The disorder affects about 10 to 20 individuals per 100,000 in the United States, according to government data. J&J acquired the drug with its $6.5 billion buyout of autoimmune disease specialist Momenta in 2020.
Reuters
21-02-2025
- Business
- Reuters
Teva Pharma and Alvotech launch biosimilar to J&J's Stelara in US
Companies Feb 21 (Reuters) - Teva Pharmaceuticals ( opens new tab and Alvotech (ALVO.O), opens new tab said on Friday they have launched a biosimilar to Johnson & Johnson's (JNJ.N), opens new tab autoimmune drug Stelara in the United States, the second in a wave of near-copies of the blockbuster treatment. J&J over the past two years has signed settlement agreements with several companies to delay the US launches of Stelara, which has been its top-selling drug since 2019. The first biosimilar, Amgen's (AMGN.O), opens new tab Wezlana, was launched in January this year. Biocon Biologics ( opens new tab is set to launch its version of the drug sometime this month, while Fresenius Kabi (FRES.M3), opens new tab is expected to follow with its own launch in April. Teva and Alvotech's Selarsdi, like Stelara, is approved for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease and ulcerative colitis. Stelara brought in revenue of $10.36 billion for J&J, making up more than 18% of the drugmaker's total drug sales of $56.96 billion for 2024. The U.S. Food and Drug Administration has allowed the use of Selarsdi as an "interchangeable" substitute only after April 30, when the exclusive rights for Amgen's Wezlana, expire. Shares of Teva Pharma rose 2.7% in premarket trading, while Alvotech's saw a 3% increase. Selarsdi has been launched in Canada as Jamteki, in Europe as Uzpruvo, and in Japan as Ustekinumab BS. In August 2020, Teva agreed to exclusively market five of Alvotech's biosimilar products in the United States. The companies extended their partnership in 2023 to include two additional biosimilars. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
